Reversible thioridazine-induced magnetic resonance imaging-documented pituitary enlargement associated with hyperprolactinemia.

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
D L MaasE C Drobny

Abstract

To document a case of reversible thioridazine-induced pituitary enlargement associated with hyperprolactinemia in a patient with schizophrenia. We describe a 19-year-old woman with paranoid schizophrenia who was taking thioridazine (a phenothiazine), in whom hyperprolactinemia, galactorrhea, oligomenorrhea, and a reversible anatomic pituitary abnormality developed. Serial magnetic resonance imaging (MRI) studies were used to assess the status of the pituitary gland during various pharmaceutical therapies. Laboratory evaluation revealed increased serum prolactin (PRL) levels that ranged from 76 to 135 mg/L. Results of thyroid function tests were normal, and gonadotropins and estradiol levels were low, consistent with hyperprolactinemia. MRI revealed asymmetric enlargement of the right side of the pituitary gland. Discontinuing the thioridazine therapy resulted in normalization of the serum PRL and resolution of the pituitary abnormality. Subsequent worsening of the patient's psychiatric condition necessitated a course of electroconvulsive therapy and initiation of treatment with clozapine, a D4 dopamine receptor antagonist. At 1-year follow-up, at which time the patient was maintained on clozapine and was not taking thioridazine...Continue Reading

References

Jan 1, 1978·Archives of General Psychiatry·P H GruenF S Halpern
Jan 1, 1979·Neuroendocrinology·T L Garthwaite, T C Hagen
Jul 1, 1975·Archives of General Psychiatry·E J SacharA G Frantz
Nov 16, 1978·European Journal of Clinical Pharmacology·R Ohman, R Axelsson
Mar 1, 1979·Molecular and Cellular Endocrinology·R A Maurer
Mar 1, 1976·Archives of General Psychiatry·H Y Meltzer, V S Fang
Mar 14, 1991·The New England Journal of Medicine·R J Baldessarini, F R Frankenburg
Nov 1, 1991·The American Journal of Psychiatry·K L DavisM Davidson
Jan 1, 1991·Acta Obstetricia Et Gynecologica Scandinavica·A DorevitchM Stark
Dec 1, 1990·The Journal of Clinical Endocrinology and Metabolism·V HermanS Melmed
Jan 1, 1985·Endocrine Reviews·N Ben-Jonathan
Feb 1, 1988·The Journal of Endocrinology·R A Prysor-JonesJ S Jenkins
Oct 1, 1985·General Hospital Psychiatry·J C Weingarten, T L Thompson
May 1, 1974·The British Journal of Psychiatry : the Journal of Mental Science·P J BeumontD H Wiles
May 1, 1974·The British Journal of Psychiatry : the Journal of Mental Science·P J BeumontD H Wiles
Jan 1, 1974·Psychopharmacologia·J A ClemensB D Sawyer
Apr 2, 1973·Biochemical and Biophysical Research Communications·C Y BowersK Folkers
Jul 1, 1981·The Journal of Clinical Endocrinology and Metabolism·H V LankfordH S Tucker
Mar 10, 1994·The New England Journal of Medicine·W T Carpenter, R W Buchanan
Sep 30, 1993·Nature·P SeemanH H Van Tol

❮ Previous
Next ❯

Citations

Apr 26, 2008·European Archives of Psychiatry and Clinical Neuroscience·Tomas HajekMartin Alda

❮ Previous
Next ❯

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.